Table 2.
Circulating plasma levels of IL6, sIL6R, sgp130, and hsCRP.
| All (n = 78) | Symptomatic (n = 53) | Asymptomatic (n = 25) | p | |
|---|---|---|---|---|
| IL6 | 2.5 (1.4–3.3) | 2.5 (1.2–3.3) | 2.3 (1.4–3.8) | 0.74 |
| sIL6R | 66.3 (50.3–82.7) | 66.1 (50.4–84.3) | 67.0 (46.0–79.7) | 0.63 |
| sgp130 | 373.9 (339.5–421.2) | 369.1 (334.5–410.4) | 386.5 (345.8–427.8) | 0.21 |
| hsCRP | 2.75 (1.3–5.0) | 2.8 (1.3–6.2) | 2.9 (1.1–4.4) | 0.64 |
| Statin (n = 65) | No statin (n = 11) | p | ||
| IL6 | 2.5 (1.5–3.3) | 1.5 (0.9–4.4) | 0.19 | |
| sIL6R | 67.0 (51.2–83.4) | 60.9 (35.4–70.0) | 0.05 | |
| sgp130 | 373.2 (339.5–413.0) | 395.3 (319.1–448.9) | 0.38 | |
| hsCRP | 2.8 (1.3–4.5) | 3.2 (1.7–7.1) | 0.54 |
Data presented as median (IQR).
Plasma concentrations expressed in pg/mL for IL6, ng/mL for sIL6R and sgp130, and mg/L for hsCRP.
Kruskal–Wallis was used to calculate the p-value for differences between subgroups. Missing information on IL6 (n = 9) and hsCRP (n = 12).
hsCRP, high-sensitivity C-reactive protein; IL6, interleukin 6; sgp130, soluble glycoprotein 130; sIL6R, soluble IL6 receptor.